Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 13/20 | 0.98 |
| ▸ | ROCK1 known ✓ | Q13464 | 12/20 | 0.98 |
| ▸ | PRKCD known ✓ | Q05655 | 5/20 | 0.98 |
| ▸ | PRKD3 known ✓ | O94806 | 4/20 | 0.98 |
| ▸ | PRKCZ known ✓ | Q05513 | 4/20 | 0.98 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.98 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.98 |
| ▸ | PRKCG known ✓ | P05129 | 3/20 | 0.61 |
| ▸ | PRKCB known ✓ | P05771 | 3/20 | 0.61 |
| ▸ | PRKCA known ✓ | P17252 | 3/20 | 0.61 |
| ▸ | PRKCH known ✓ | P24723 | 3/20 | 0.61 |
| ▸ | PRKCI known ✓ | P41743 | 3/20 | 0.61 |
| ▸ | PRKCE known ✓ | Q02156 | 3/20 | 0.61 |
| ▸ | PRKCQ known ✓ | Q04759 | 3/20 | 0.61 |
| ▸ | PRKD1 known ✓ | Q15139 | 3/20 | 0.61 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL507871 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2460111 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL29396389 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL29781011 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2461354 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2456059 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL30009735 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL29372951 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL30069136 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL124161 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371664-B2 | Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby | CHA BIOTECH CO., LTD. (KR) | 2025-07-29 | — | — | US | claimed |
| US-20210340498-A1 | MEDIUM FOR DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL, METHOD FOR PREPARING MESENCHYMAL STEM CELL BY USING SAME, AND MESENCHYMAL STEM CELL PREPARED THEREBY | CHA BIOTECH CO., LTD. (KR) | 2021-11-04 | — | — | US | claimed |
| EP-3848455-A1 | MEDIUM FOR DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL, METHOD FOR PREPARING MESENCHYMAL STEM CELL BY USING SAME, AND MESENCHYMAL STEM CELL PREPARED THEREBY | CHA Biotech Co., Ltd. (KR) | 2021-07-14 | — | — | EP | claimed |
| CN-112996903-A | Culture medium for directly differentiating pluripotent stem cell-derived mesenchymal stem cells, method for preparing mesenchymal stem cells by using culture medium and mesenchymal stem cells prepared by using culture medium | 车比奥泰有限公司 | 2021-06-18 | — | — | CN | claimed |
| US-20190194608-A1 | ISOLATION OF NON-EMBRYONIC STEM CELLS AND USES THEREOF | THE JACKSON LABORATORY | 2019-06-27 | — | — | US | claimed |
| US-20180282690-A1 | METHOD AND CULTURE MEDIUM FOR EX VIVO CULTURING OF EPIDERMIS-DERIVED STEM CELLS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-10-04 | — | — | US | claimed |
| EP-2718422-B1 | CULTURE MEDIA FOR STEM CELLS | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (KNAW) (NL) | 2017-09-06 | — | — | EP | claimed |
| US-20170233698-A1 | CULTURED MAMMALIAN LIMBAL STEM CELLS, METHODS FOR GENERATING THE SAME, AND USES THEREOF | YOUHEALTH BIOTECH, LIMITED (KY) | 2017-08-17 | — | — | US | claimed |
| EP-3161127-A1 | CULTURED MAMMALIAN LIMBAL STEM CELLS, METHODS FOR GENERATING THE SAME, AND USES THEREOF | The Regents of the University of California (US) | 2017-05-03 | — | — | EP | claimed |
| US-20160237400-A1 | ISOLATION OF NON-EMBRYONIC STEM CELLS AND USES THEREOF | THE JACKSON LABORATORY (US) | 2016-08-18 | — | — | US | claimed |
| WO-2015200920-A1 | CULTURED MAMMALIAN LIMBAL STEM CELLS, METHODS FOR GENERATING THE SAME, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-30 | — | — | WO | claimed |
| EP-2718422-A2 | CULTURE MEDIA FOR STEM CELLS | Koninklijke Nederlandse Akademie van Wetenschappen (KNAW) (NL) | 2014-04-16 | — | — | EP | claimed |
| WO-2012168930-A2 | Culture media for stem cells | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (KNAW) (NL) | 2012-12-13 | — | — | WO | claimed |
| US-20120010196-A1 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS AND DISEASES | WESTERN UNIVERSITY OF HEALTH SCIENCES | 2012-01-12 | — | — | US | claimed |
| US-12618830-B2 | Methods, culture medias and devices for generating embryos in vitro from stem cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2026-05-05 | — | — | US | disclosed |
| EP-3690022-B1 | CELL CULTURE MEDIUM FOR CULTURING ORGANOID, CULTURE METHOD, AND ORGANOID | UNIV KEIO (JP) | 2026-03-18 | — | — | EP | disclosed |
| US-12467917-B2 | Reconstructing human early embryogenesis in vitro with pluripotent stem cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-11-11 | — | — | US | disclosed |
| US-20120028355-A1 | CULTURE MEDIUM FOR EPITHELIAL STEM CELLS AND ORGANOIDS COMPRISING SAID STEM CELLS | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2012-02-02 | — | — | US | disclosed |
| US-20120010196-A1 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS AND DISEASES | WESTERN UNIVERSITY OF HEALTH SCIENCES | 2012-01-12 | — | — | US | disclosed |
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194608-A1 | ISOLATION OF NON-EMBRYONIC STEM CELLS AND USES THEREOF | ALPG, MKI67, NES | ROCK2 2855/4885ROCK1 2893/4885PRKCD 2321/4885 |
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | RHOA, LIPG, KDR | ROCK2 9/4885ROCK1 8/4885PRKCD 294/4885 |
| US-20160237400-A1 | ISOLATION OF NON-EMBRYONIC STEM CELLS AND USES THEREOF | ALPG, MKI67, NES | ROCK2 2855/4885ROCK1 2893/4885PRKCD 2321/4885 |
| US-12618830-B2 | Methods, culture medias and devices for generating embryos in vitro from stem cells | POU2F1, POU5F1, POU2F2 | ROCK2 2165/4885ROCK1 2793/4885PRKCD 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.